Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Potential role of IL-13 in neuroprotection and cortical excitability regulation in multiple sclerosis.

Rossi S, Mancino R, Bergami A, Mori F, Castelli M, De Chiara V, Studer V, Mataluni G, Sancesario G, Parisi V, Kusayanagi H, Bernardi G, Nucci C, Bernardini S, Martino G, Furlan R, Centonze D.

Mult Scler. 2011 Nov;17(11):1301-12. doi: 10.1177/1352458511410342. Epub 2011 Jun 15.

PMID:
21677024
2.

Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis.

Rossi S, Furlan R, De Chiara V, Motta C, Studer V, Mori F, Musella A, Bergami A, Muzio L, Bernardi G, Battistini L, Martino G, Centonze D.

Ann Neurol. 2012 Jan;71(1):76-83. doi: 10.1002/ana.22512.

PMID:
22275254
3.

Brain excitability changes in the relapsing and remitting phases of multiple sclerosis: a study with transcranial magnetic stimulation.

Caramia MD, Palmieri MG, Desiato MT, Boffa L, Galizia P, Rossini PM, Centonze D, Bernardi G.

Clin Neurophysiol. 2004 Apr;115(4):956-65.

PMID:
15003779
4.

Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings.

Fainardi E, Rizzo R, Melchiorri L, Vaghi L, Castellazzi M, Marzola A, Govoni V, Paolino E, Tola MR, Granieri E, Baricordi OR.

J Neuroimmunol. 2003 Sep;142(1-2):149-58.

PMID:
14512174
5.

Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis.

Bock M, Brandt AU, Kuchenbecker J, Dörr J, Pfueller CF, Weinges-Evers N, Gaede G, Zimmermann H, Bellmann-Strobl J, Ohlraun S, Zipp F, Paul F.

Br J Ophthalmol. 2012 Jan;96(1):62-7. doi: 10.1136/bjo.2010.193581. Epub 2011 Mar 3.

PMID:
21378002
6.

Cortical dysfunction underlies disability in multiple sclerosis.

Vucic S, Burke T, Lenton K, Ramanathan S, Gomes L, Yannikas C, Kiernan MC.

Mult Scler. 2012 Apr;18(4):425-32. doi: 10.1177/1352458511424308. Epub 2011 Sep 30.

PMID:
21965421
7.

Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis.

Zaveri MS, Conger A, Salter A, Frohman TC, Galetta SL, Markowitz CE, Jacobs DA, Cutter GR, Ying GS, Maguire MG, Calabresi PA, Balcer LJ, Frohman EM.

Arch Neurol. 2008 Jul;65(7):924-8. doi: 10.1001/archneur.65.7.924.

PMID:
18625859
8.
9.

Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.

Augutis K, Axelsson M, Portelius E, Brinkmalm G, Andreasson U, Gustavsson MK, Malmeström C, Lycke J, Blennow K, Zetterberg H, Mattsson N.

Mult Scler. 2013 Apr;19(5):543-52. doi: 10.1177/1352458512460603. Epub 2012 Oct 15.

PMID:
23069872
10.

T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis.

Ruocco G, Rossi S, Motta C, Macchiarulo G, Barbieri F, De Bardi M, Borsellino G, Finardi A, Grasso MG, Ruggieri S, Gasperini C, Furlan R, Centonze D, Battistini L, Volpe E.

Clin Sci (Lond). 2015 Aug;129(4):291-303. doi: 10.1042/CS20140608.

PMID:
25700150
11.

Neuronal apoptosis induced by cerebrospinal fluid from multiple sclerosis patients correlates with hypointense lesions on T1 magnetic resonance imaging.

Cid C, Alcázar A, Regidor I, Masjuan J, Salinas M, Alvarez-Cermeño JC.

J Neurol Sci. 2002 Jan 15;193(2):103-9.

PMID:
11790390
12.

Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis.

Rossi S, Studer V, Motta C, Germani G, Macchiarulo G, Buttari F, Mancino R, Castelli M, De Chiara V, Weiss S, Martino G, Furlan R, Centonze D.

J Neuroinflammation. 2014 Feb 18;11:32. doi: 10.1186/1742-2094-11-32.

13.

Significant correlation between IL-10 levels and IgG indices in the cerebrospinal fluid of patients with multiple sclerosis.

Nakashima I, Fujihara K, Misu T, Okita N, Takase S, Itoyama Y.

J Neuroimmunol. 2000 Nov 1;111(1-2):64-7.

PMID:
11063822
14.

Rapid-onset central motor plasticity in multiple sclerosis.

Zeller D, aufm Kampe K, Biller A, Stefan K, Gentner R, Schütz A, Bartsch A, Bendszus M, Toyka KV, Rieckmann P, Classen J.

Neurology. 2010 Mar 2;74(9):728-35. doi: 10.1212/WNL.0b013e3181d31dcf.

PMID:
20194911
15.

Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM.

Sola P, Mandrioli J, Simone AM, Ferraro D, Bedin R, Annecca R, Venneri MG, Nichelli PF, Merelli E.

Mult Scler. 2011 Mar;17(3):303-11. doi: 10.1177/1352458510386996. Epub 2010 Nov 15.

PMID:
21078694
16.

Cortical relay time for long latency reflexes in patients with definite multiple sclerosis.

Tataroglu C, Genc A, Idiman E, Cakmur R, Idiman F.

Can J Neurol Sci. 2004 May;31(2):229-34.

PMID:
15198449
17.

Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis.

Burkholder BM, Osborne B, Loguidice MJ, Bisker E, Frohman TC, Conger A, Ratchford JN, Warner C, Markowitz CE, Jacobs DA, Galetta SL, Cutter GR, Maguire MG, Calabresi PA, Balcer LJ, Frohman EM.

Arch Neurol. 2009 Nov;66(11):1366-72. doi: 10.1001/archneurol.2009.230.

PMID:
19901168
18.

Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis.

Pueyo V, Martin J, Fernandez J, Almarcegui C, Ara J, Egea C, Pablo L, Honrubia F.

Mult Scler. 2008 Jun;14(5):609-14. doi: 10.1177/1352458507087326. Epub 2008 Apr 18.

PMID:
18424482
19.

Relating axonal injury to functional recovery in MS.

Reddy H, Narayanan S, Matthews PM, Hoge RD, Pike GB, Duquette P, Antel J, Arnold DL.

Neurology. 2000 Jan 11;54(1):236-9.

PMID:
10636158
20.

Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression.

Moldovan IR, Rudick RA, Cotleur AC, Born SE, Lee JC, Karafa MT, Pelfrey CM.

J Neuroimmunol. 2003 Aug;141(1-2):132-40.

PMID:
12965264

Supplemental Content

Support Center